Alcohol consumption \> 20g/day

Type 1 diabetes or poorly controlled diabetes mellitus (HbA1c ≥ 9%)

Evidence of other chronic liver disease (e.g. HBsAg positive, anti-HCV positive, autoimmune hepatitis, Wilson's disease, alpha-1 antitrypsin deficiency and etc.)

ALT, AST \> 5X the upper limit of normal

Serum creatinine ≥ 2mg/dl

Fibrosis score ≥ 3 according to the NASH CRN fibrosis staging system

NQO1 T/T type

Weight loss of more than 5kg within 6 months

Bariatric surgery within 6 months

Known alcohol or any other drug abuse in the last five years

Insulin sensitizers, hepatoprotective agents, anti-oxidants, lipid-lowering agents, drugs induced fatty liver within 1 month

Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis

What this study is about